Given that epigenetic therapeutics, including HDAC-inhibitors are in clinical use in AML, our data supports the further investigation of NKG2D-CAR T cell therapy in conjunction with pharmacologic HDAC-inhibition in xenograft models of AML as a rational combination therapy with synergistic anti-leukemia effects. The gene discussed is HDAC9; the disease is leukemia.